Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,366 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting of intracellular oncoproteins with peptide-centric CARs.
Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, Li W, di Marco M, Runbeck E, Truong H, Toor JS, Tripathi S, Nguyen S, Shen H, Noel T, Church NL, Weiner A, Kendsersky N, Martinez D, Weisberg R, Christie M, Eisenlohr L, Bosse KR, Dimitrov DS, Stevanovic S, Sgourakis NG, Kiefel BR, Maris JM. Yarmarkovich M, et al. Among authors: martinez d. Nature. 2023 Nov;623(7988):820-827. doi: 10.1038/s41586-023-06706-0. Epub 2023 Nov 8. Nature. 2023. PMID: 37938771 Free PMC article.
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.
Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, Li W, di Marco M, Runbeck E, Truong H, Toor JS, Tripathi S, Nguyen S, Shen H, Noel T, Church NL, Weiner A, Kendsersky N, Martinez D, Weisberg R, Christie M, Eisenlohr L, Bosse KR, Dimitrov DS, Stevanovic S, Sgourakis NG, Kiefel BR, Maris JM. Yarmarkovich M, et al. Among authors: martinez d. Nature. 2021 Nov;599(7885):477-484. doi: 10.1038/s41586-021-04061-6. Epub 2021 Nov 3. Nature. 2021. PMID: 34732890 Free PMC article. Retracted.
Retraction Note: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.
Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, Li W, di Marco M, Runbeck E, Truong H, Toor JS, Tripathi S, Nguyen S, Shen H, Noel T, Church NL, Weiner A, Kendsersky N, Martinez D, Weisberg R, Christie M, Eisenlohr L, Bosse KR, Dimitrov DS, Stevanovic S, Sgourakis NG, Kiefel BR, Maris JM. Yarmarkovich M, et al. Among authors: martinez d. Nature. 2023 Nov;623(7988):872. doi: 10.1038/s41586-023-06731-z. Nature. 2023. PMID: 37938785 Free PMC article. No abstract available.
A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope.
Raman S, Buongervino SN, Lane MV, Zhelev DV, Zhu Z, Cui H, Martinez B, Martinez D, Wang Y, Upton K, Patel K, Rathi KS, Navia CT, Harmon DB, Li Y, Pawel B, Dimitrov DS, Maris JM, Julien JP, Bosse KR. Raman S, et al. Among authors: martinez d, martinez b. Cell Rep Med. 2021 Jul 21;2(7):100344. doi: 10.1016/j.xcrm.2021.100344. eCollection 2021 Jul 20. Cell Rep Med. 2021. PMID: 34337560 Free PMC article.
Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.
Bosse KR, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, Rathi KS, Kendsersky NM, Randall M, Donovan L, Morrissy S, Sussman RT, Zhelev DV, Feng Y, Wang Y, Hwang J, Lopez G, Harenza JL, Wei JS, Pawel B, Bhatti T, Santi M, Ganguly A, Khan J, Marra MA, Taylor MD, Dimitrov DS, Mackall CL, Maris JM. Bosse KR, et al. Among authors: martinez d. Cancer Cell. 2017 Sep 11;32(3):295-309.e12. doi: 10.1016/j.ccell.2017.08.003. Cancer Cell. 2017. PMID: 28898695 Free PMC article.
CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma.
Sussman RT, Rokita JL, Huang K, Raman P, Rathi KS, Martinez D, Bosse KR, Lane M, Hart LS, Bhatti T, Pawel B, Maris JM. Sussman RT, et al. Among authors: martinez d. Front Oncol. 2020 Mar 6;10:302. doi: 10.3389/fonc.2020.00302. eCollection 2020. Front Oncol. 2020. PMID: 32211329 Free PMC article.
Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.
Krytska K, Casey CE, Pogoriler J, Martinez D, Rathi KS, Farrel A, Berko ER, Tsang M, Sano RR, Kendsersky N, Erickson SW, Teicher BA, Isse K, Saunders L, Smith MA, Maris JM, Mossé YP. Krytska K, et al. Among authors: martinez d. Cancer Res Commun. 2022 Jul;2(7):616-623. doi: 10.1158/2767-9764.crc-22-0137. Epub 2022 Jul 11. Cancer Res Commun. 2022. PMID: 36381237 Free PMC article.
GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies.
Pascual-Pasto G, McIntyre B, Shraim R, Buongervino SN, Erbe AK, Zhelev DV, Sadirova S, Giudice AM, Martinez D, Garcia-Gerique L, Dimitrov DS, Sondel PM, Bosse KR. Pascual-Pasto G, et al. Among authors: martinez d. J Immunother Cancer. 2022 Dec;10(12):e004704. doi: 10.1136/jitc-2022-004704. J Immunother Cancer. 2022. PMID: 36460335 Free PMC article.
The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models.
Kendsersky NM, Lindsay J, Kolb EA, Smith MA, Teicher BA, Erickson SW, Earley EJ, Mosse YP, Martinez D, Pogoriler J, Krytska K, Patel K, Groff D, Tsang M, Ghilu S, Wang Y, Seaman S, Feng Y, Croix BS, Gorlick R, Kurmasheva R, Houghton PJ, Maris JM. Kendsersky NM, et al. Among authors: martinez d. Clin Cancer Res. 2021 May 15;27(10):2938-2946. doi: 10.1158/1078-0432.CCR-20-4221. Epub 2021 Feb 22. Clin Cancer Res. 2021. PMID: 33619171 Free PMC article.
2,366 results